Solving Imminent Regulatory Challenges With Single Use Technologies For mRNA Vaccine Production
By Ben Wylie
![mRNA iStock-1287178753 mRNA iStock-1287178753](https://vertassets.blob.core.windows.net/image/612e6b1c/612e6b1c-d83a-4aff-a70a-4c4c9080b3b4/375_250-mrna_istock_1287178753.jpg)
The market for mRNA (messenger Ribonucleic Acid) vaccine technology is expanding rapidly. mRNA vaccines stimulate the immune response in a patient’s body. Instead of the vaccine containing a weakened/inactivated form of the virus, the vaccine contains genetic material coding for a disease-specific protein to the virus. Though manufacturing, mRNA technology comes with a list of challenges, the biggest obstacle being achieving compliance with GMP Annex 1 regulations. Here, we dive into the compliance issue and explain how companies who want to use mRNA vaccine technology can address challenges through the use of single-use technologies (SUTs).
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.